

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

Sheet 1 of 6

Complete if Known

Application Number	10/525,115
Filing Date	August 31, 2005
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Jeffrey H. Murray
Attorney Docket Number	01-2112

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	US- 3 165 520	01-1965	SCHMIDT ET AL.	
	A2	US- 5 041 449	08-20-1991	BELLEAU ET AL.	
	A3	US- 5 047 407	09-10-1991	BELLEAU ET AL.	
	A4	US- 5 053 499	10-01-1991	KOJIMA ET AL.	
	A5	US- 5 270 315	12-14-1993	BELLEAU ET AL.	
	A6	US- 5 294 612	03-15-1994	BACON ET AL.	
	A7	US- 5 466 806	11-14-1995	BELLEAU ET AL.	
	A8	US- 5 541 187	07-30-1996	BACON ET AL.	
	A9	US- 5 563 049	10-08-1996	KOJIMA ET AL.	
	A10	US- 5 684 164	11-04-1997	BELLEAU ET AL.	
	A11	US- 5 750 673	05-12-1998	MARTIN, PIERRE	
	A12	US- 5 948 812	09-07-1999	KRAFT, PHILIP	
	A13	US- 5 969 499	10-19-1999	SHAFFER RANDALL A	
	A14	US- 5 977 332	11-02-1999	MARTIN, PIERRE	
	A15	US- 6 100 037	08-08-2000	PHILLIPS ET AL.	
	A16	US- 6 175 008	01-16-2001	BELLEAU ET AL.	
	A17	US- 6 174 884	01-16-2001	HANING ET AL.	
	A18	US- 6 211 158	04-03-2001	SEELA ET AL.	
	A19	US- 6 225 315	05-01-2001	ELLIS PETER	
	A20	US- 2001 041797	11-15-2001	BELLEAU ET AL.	
	A21	US- 6 831 174	11-15-2001	BELLEAU ET AL.	
	A22	US- 2001 0044441	11-22-2001	CAMPBELL ET AL.	
	A23	US- 6 350 753	02-26-2002	BELLEAU ET AL.	
	A24	US- 2002 0586635	05-16-2002	VARMING ET AL.	
	A25	US- 2002 074774	06-20-2002	HSU ET AL.	
	A26	US- 2002 086160	07-04-2002	QIU ET AL.	
	A27	US- 2002 0132754	09-19-2002	BOSS ET AL.	
	A28	US- 6 479 463	11-12-2002	WANG ET AL.	
	A29	US- 2002 16348	11-28-2002	RABINOWITZ ET AL.	
	A30	US- 2003 087918	05-08-2003	BELLEAU ET AL.	
	A31	US- 6 903 224	05-08-2003	BELLEAU ET AL.	
	A32	US- 2004 185459	09-23-2004	OTSUKA ET AL.	
	A33	US- 2004 220186	11-04-2004	BELL ET AL.	
	A34	US- 2004 254201	12-16-2004	BELLEAU ET AL.	
	A35	US- 7 122 693	12-16-2004	BELLEAU ET AL.	
	A36	US- 2005 209251	09-22-2005	LINKER ET AL.	
	A37	US- 7 022 709	04-04-2006	BÖESS ET AL.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/525,115
				Filing Date	August 31, 2005
				First Named Inventor	Martin Hendrix
				Art Unit	1624
				Examiner Name	Jeffrey H. Murray
				Attorney Docket Number	01-2112
Sheet	2	of	6		

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A38	US- 7 737 156	05-11-2006	BOSS ET AL.	
	A39	US- 2007 037977	02-15-2007	BELLEAU ET AL.	
	A40	US- 2007 0105876	05-10-2007	HENDRIX ET AL.	
	A41	US- 2009 121919	05-14-2009	KIHARA ET AL.	
	A42	US-7 737 156	06-15-2010	BÖESS ET AL.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	B1	GB- 937 723	09-25-1963	CIBA LTD		
	B2	CH- 396 923	08-15-1965	CIBA GEIGY		C31
	B3	EP-0 286 028	10-12-1988	BOEHRINGER MANNHEIM GMBH		B6
	B4	DE-4 004 558	09-27-1990	SANYO KOKUSAKU PULP CO		A4
	B5	EP-0 496 617	07-29-1992	GENSIA PHARMA		
	B6	CA-1 311 201	12-08-1992	BOEHRINGER MANNHEIM GMBH		
	B7	WO-94 14802	07-07-1994	BELLEAU PIERRETTE & HF		
	B8	WO-94 17803	08-18-1994	GENSIA INC		
	B9	EP-0 626 387	11-30-1994	CIBA GEIGY AG		
	B10	EP-0 679 657	11-02-1995	CIBA GEIGY AG		A11
	B11	WO-97 16456	05-09-1997	CHONG KUN DANG CORP		
	B12	WO-97 46569	12-11-1997	CIBA GEIGY AG		
	B13	WO-98 00434	01-08-1998	CIBA GEIGY AG		
	B14	WO-98 16184	04-23-1998	ICN PHARMACEUTICAL S		
	B15	CA-2 283 211	09-17-1998	BAYER AG		
	B16	CA- 2 238 211	12-09-1998	GIVAUDAN ROURE INT		A12
	B17	JP-11-501923	02-16-1999			
	B18	CA-2 357 146	07-13-2000	INCYTE PHARMA INC		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

Sheet 3 of 6

Complete if Known

Application Number	10/525,115
Filing Date	August 31, 2005
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Jeffrey H. Murray
Attorney Docket Number	01-2112

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	B19	WO-2000 043394	07-27-2000	USTAV EX BOTAN AKADEMIE VED CE		
	B20	WO-2001 060315	08-23-2001	IAF BIOCHEM INT		
	B21	JP-2001 514638	09-11-2001	BAYER AG		A17
	B22	WO-2001 077075	10-18-2001	INOTEK CORP		
	B23	WO-2002 09713	02-07-2002	BAYER AG		A37
	B24	WO-2002 16348	02-28-2002	ASTRAZENECA AB		
	B25	WO-2002 057425	07-25-2002	MERCK & CO INC		
	B26	WO-2002 074774	09-26-2002	PFIZER LTD		
	B27	WO-2002 086160	10-31-2002	DAIICHI KASEI RAYON CO		A32
	B28	CA-2 417 631	01-29-2003	BAYER AG		
	B29	WO-2003 022859	03-20-2003	EPOCH BIOSCIENCES INC		
	B30	CA-2 466 824	05-08-2003	PFIZER		
	B31	WO-2003 072757	09-04-2003	BIOTA INC		
	B32	CA-2 484 997	11-13-2003	BAYER CROPSCIENCE AG		
	B33	WO-2004 002999	01-08-2004	IDENIX CAYMAN LTD		
	B34	WO-2004 018474	03-04-2004	BAYER HEALTHCARE AG		
	B35	DE-102 38 722	03-11-2004	BAYER AG		
	B36	WO-2004 026876	04-01-2004	BAYER HEALTHCARE AG		
	B37	WO-2004 026286	04-01-2004	BAYER HEALTHCARE AG		A42
	B38	WO-2004 046331	06-03-2004	IDENIX CAYMAN LTD		
	B39	EP-1 460 077	09-22-2004	JORDANIAN PHARMACEUTICAL MFG		
	B40	JP-2004 536933	12-09-2004	PPG IND OHIO INC		B60
	B41	WO-2004 108139	12-16-2004	AREXIS AB		
	B42	WO-2001 05758	01-25-2005	NPS ALLELIX CORP		
	B43	WO-2005 051944	06-09-2005	UNIV CONNECTICUT		
	B44	JP-2005 531549	10-20-2005	BAYER CROPSCIENCE AG		A36
	B45	JP-2006 501272	01-12-2006	BOEHRINGER INGELHEIM INT		A42
	B46	JP-2006 503051	01-26-2006	BAYER HEALTHCARE AG		
	B47	WO-2006 084281	08-10-2006	MILLENNIUM PHARM INC		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

Sheet 4 of 6

Complete if Known

Application Number	10/525,115
Filing Date	August 31, 2005
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Jeffrey H. Murray
Attorney Docket Number	01-2112

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	B48	WO-2006 091095	08-31-2006	STICHTING ENERGIE		
	B49	WO-2007 025043	03-01-2007	IDENIX PHARMACEUTICAL S INC		
	B50	WO-2007 046747	04-26-2007	ASTRAZENECA AB		
	B51	WO-2008 005542	01-10-2008	GILEAD SCIENCES INC		
	B52	WO-2008 10047	01-24-2008	INST NAT SANTE RECH MED		
	B53	WO-2008 055959	05-15-2008	GALAPAGOS N V		
	B54	WO-2008 100447	08-21-2008	GILEAD SCIENCES INC		
	B55	WO-2008 104077	09-04-2008	METHYLGENE INC		
	B56	WO-2008 139293	11-20-2008	PFIZER		
	B57	WO-2009 068617	06-04-2009	BOEHRINGER INGELHEIM INT		
	B58	WO-2010 026214	03-11-2010	BOEHRINGER INGELHEIM INT		
	B59	WO-2010 112437	10-07-2010	BOEHRINGER INGELHEIM INT		
	B60	WO-2003 011925	02-13-2003	PPG IND OHIO INC		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	BARGER ET AL., "Role of cyclic GMP in the Regulation of Neuronal Calcium and Survival by Secreted Forms of Beta-Amyloid Precursor," J of Neurochem, 1995, Vol. 64, No. 5, pp. 2087-2096	
	C2	BYRN ET AL., Solid State Chemistry of Drugs, 1999, Vol. 2, No 10, pp. 232-247	
	C3	Chem Abstracts Service, Database Accession No. ALB-H01677136, Database Chemcats, 2007, XP002556399	
	C4	CHENG ET AL., "Potential Purine Antagonists VII. Synthesis of 6-Alkylpyrazolo-[3,4-d]pyrimidines" Potential Purine Antagonist VII, 1958, Vol. 23, pp. 191-200	
	C5	DOERWALD ET AL., "Side reactions in organic synthesis," A Guide to Successful Synthesis Design, 2005, 4 pages	
	C6	EBERT ET AL., "Scopolamine model of dementia: electroencephalogram findings and cognitive performance," Europ J of Clinical Investigation, 1998, Vol. 28, No. 11, pp. 944-949	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 6

Complete if Known

Application Number	10/525,115
Filing Date	August 31, 2005
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Jeffrey H. Murray
Attorney Docket Number	01-2112

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C7	HARB ET AL., "Pyrazoles as building blocks in heterocyclic synthesis...", Chemical Papers, 2005, Vol. 59, No. 3, pp. 187-159, XP002498868	
	C8	HUNG ET AL., "A high-yielding synthesis of monalkylhydrazines," Journal of Organic Chemistry, 1981, Vol. 46, pp. 5413-5414	
	C9	International Search Report for PCT/EP2004/006477 dated October 27, 2004	
	C10	International Search Report for PCT/EP2004/014872 dated May 19, 2005	
	C11	International Search Report of PCT/EP2003/08880 dated April 16, 2004	
	C12	International Search Report of PCT/EP2003/08923 dated December 15, 2003	
	C13	International Search Report of PCT/EP2003/08979 dated November 25, 2003	
	C14	International Search Report of PCT/EP2004/004412 dated July 14, 2004	
	C15	International Search Report of PCT/EP2004/004455 dated September 17, 2004	
	C16	MARKWALDER, J. A. ET AL., "Synthesis and Biological Evaluation of 1-Aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one Inhibitors of Cyclin-Dependent Kinases," J of Med Chemistry, 2004, Vol. 47, pp. 5894-5911, XP002399637	
	C17	PODRAZA ET AL., "Reductive Cyclization of Ketoesters Utilizing Sodium Cyanoborohydride: Synthesis of γ - and δ -lactones," J of Heterocyclic Chem., 1987, Vol. 24, pp. 293	
	C18	PRICKAERTS ET AL., "Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic gmp levels in the rat," Neuroscience, 2002, Vol. 113, pp. 351-361	
	C19	PRICKAERTS ET AL., "Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: Effects of 7 nitroindazole and zaprinast," Europ J of Pharmacology, 1997, Vol. 337, No. 2-3, pp. 125-136	
	C20	REID ET AL., Current Pharmaceutical Design, 1999, Vol. 5, No. 9, pp. 725-735	
	C21	SCHMIDT ET AL., "Pyrazolo[3, 4-d] pyrimidin-nucleoside," Chemische Berichte, 1977, Vol. 110, pp. 2445-2455	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

6

of

6

Complete if Known

Application Number

10/525,115

Filing Date

August 31, 2005

First Named Inventor

Martin Hendrix

Art Unit

1624

Examiner Name

Jeffrey H. Murray

Attorney Docket Number

01-2112

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C22	SKIPPER ET AL., "Structure-Activity Relationships Observed on Screening a Series of Pyrazolopyrimidines against Experimental Neoplasms," Cancer Research, 1957, Vol. 17, pp. 579-596	
	C23	TIMBERLAKE ET AL., "Chemistry of Hydrazo-, Azo-, and Azoxy Groups," Patai, 1975, Chapter 4	
	C24	UGARKAR ET AL., "Synthesis and antiviral/antitumor activities of...", Journal of Medicinal Chemistry, 1984, Vol. 27, No. 8, pp. 1026-1030	
	C25	ULRICH ET AL., "Crystallization," Kirk-Othmer Encyclopedia of Chem. Techn., 2002, 7 pages	
	C26	VAN STAVEREN ET AL., "Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain," Journal of Neurocytology, 2002, Vol. 31, pp. 729-741	
	C27	WANG ET AL., "Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase-splice variant (PDE9A5) Different tissue distribution and subcellular localization of PDE9A variants," Gene, 2003, Vol. 314, pp. 15-27	
	C28	WEEBER ET AL., "Molecular genetics of human cognition," Molecular Interventions, 2002, Vol. 2, No. 6, pp. 376-391	
	C29	WEST ET AL., "Solid Solutions," Dept of Chem Univ of Aberdeen, 1988, Vol. 18, 3 pages	
	C30	CIBA GEIGY AG, "Nucleosides and oligonucleotides and 2'-ether groups," Data Supplied from the espacenet database, Publication Date: November 30, 1994; English Abstract of EP0 626 387	
	C31	THOMSON INNOVATION RECORD VIEW, Publication Date: August 15, 1965; English Abstract of CH 396 923	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2